Press release content from Globe Newswire. The AP news staff was not involved in its creation. Biofrontera reports Q1 2021 financial results Biofrontera AGMay 11, 2021 GMT Leverkusen, Germany, May 11, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2021. Q1 2021 key financial figures and business performance In EUR thousands ADVERTISEMENT Biofrontera’s business performance was encouragingly positive after an initial, pandemic-related slow start at the beginning of the year. As expected, business activities and consequently sales continue to be heavily dependent on the development of the pandemic and the related easing of lockdown measures in our sales markets. While sales in the first quarter were 15% lower overall than in the same period of the previous year, the sales development since March shows a very positive trend,” summarizes Prof. Dr. Lübbert, CEO of Biofrontera. “This trend has continued into April 2021, indicating a stable recovery of the general pandemic situation in our sales markets, especially in the USA. April sales are also particularly encouraging when compared to 2019, i.e. monthly sales before the pandemic. Compared to that year, preliminary sales figures for April 2021 show an 8% increase in product sales in all markets. Compared to April 2019, April 2021 sales in the US increased by 3%, in Germany by 25% and in the remaining European markets by 20%.”